Observational studyAnnals of hematology2025

Polatuzumab Vedotin, zanubrutinib and rituximab (Pola-ZR) achieved rapid and deep response in untreated frail and elderly DLBCL.

Yuhong Ren et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.